A Study of Chidamide With AZA in MRD Positive AML After Transplant
Study Details
Study Description
Brief Summary
acute myeloid leukemia (AML) is a malignant tumor of the hematopoietic system with high heterogeneity in cytogenetics and molecular biology.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is still the primary treatment option for patients with AML and the most effective method for radical treatment of AML.Despite considerable progress in allo-HSCT over the past decade, 30%-40% of patients still relapse, and post-transplant relapse remains the leading cause of death in patients with AML.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
N/A |
Detailed Description
Investigators proposed Chidamide combined with azacitidine as the prospective treatment for MRD-positive AML patients before and after transplantation, hoping to reduce the recurrence rate of transplantation and improve the transplantation effect. The efficacy and safety of the method will be verified by this clinical study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: chidamide and azacitidine
|
Drug: chidamide and azacitidine
chidamide:10mg orally,day 1 to day 6 every week, Take it for two weeks, rest for two weeks,so 28 days for a circle, 12 circles totally.
azacitidine:50mg,subcutaneous injection,day 1 to day 5 every week, 28 days for a circle, 6 circles totally.
|
Outcome Measures
Primary Outcome Measures
- the rate of RFS in 6 months [6 months]
relapse-free survival
Secondary Outcome Measures
- the rate of MRD turn negative in 6 months [6 months]
minimal residual disease turn negative
- the time length of MRD negative [24 months]
minimal residual disease negative
- the 1 year/2 year RFS [24 months]
relapse-free survival
- the 1 year/2 year OS [24 months]
overall survival
- the rate of GVHD [24 months]
graft-versus-host disease
- Incidence of Treatment-Emergent Adverse Events [24 months]
Grade 1 to Grade 4 ,according to Common Terminology Criteria for Adverse Events, versions 5.0
Other Outcome Measures
- T cell receptor excision circles (TRECs) level before and after treatment [24 months]
T cell receptor excision circles (TRECs) are released upon rearrangement of the T cell receptor.
- the rate of MRD turn negative in molecular genetic abnormality subtype [24 months]
minimal residual disease
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients diagnosed with AML (diagnostic criteria refer to WHO2016 criteria, except M3) can detect small residual lesions (MRD) positive after allogeneic hematopoietic stem cell transplantation (allo-HSCT);
-
≥18 years old;
-
ECOG≤3;
-
lifespan≥3 months;
-
Take contraceptive measures;
-
Sign informed consent.
Exclusion Criteria:
-
Allergic to the study drug;
-
A gastrointestinal condition that prevents oral medication;
-
active infection;
-
Dysfunction of vital organs;
-
other malignancies;
-
HIV infection;
-
HBV or HCV;
-
The QT interval is prolonged;
-
Pregnant or lactating women;
-
Is participating in other clinical studies;
-
The researchers did not consider it appropriate to participate in this study.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Guangdong Provincial People's Hospital | Guangzhou | Guangdong | China |
Sponsors and Collaborators
- Guangdong Provincial People's Hospital
- Shenzhen Chipscreen Biosciences Co.Ltd
Investigators
- Principal Investigator: WENG jian yu, M.D., Department of Hematology, Guangdong Provincial People's Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- Chidaza101